Thyroid Hormone Replacement in Patients With Septic Shock
Status:
Not yet recruiting
Trial end date:
2023-03-15
Target enrollment:
Participant gender:
Summary
The primary aim of the study would be to determine whether there is a difference in survival
in the Intensive Care Unit between the group of patients with septic shock diagnosed with
euthyroid sick syndrome who were treated with T3 hormone compared to the group of patients
not treated with this hormone. Secondary objectives of the research would be:
Compare the level of thyroid hormones between the examined groups and
1. laboratory indicators of septic shock (C-reactive protein-CRP, procalcitonin,
leukocytes, acid-base status, lactates)
2. APACHE II, SOFA and SAPS II patient assessment scales,
3. inflammatory prognostic systems (ratio of CRP and albumin-modified Glasgow prognostic
score-mGPS, ratio of neutrophils and lymphocytes - NLR, ratio of platelets and
lymphocytes - PLR, and ratio of leukocytes and CRP, prognostic index - PI)
4. hemodynamic stability of patients (MAP, systolic and diastolic pressure) in the periods
of admission T0, T3, T6, T12, T24 and every 24 hours for 4 days,
5. effect of vasoactive drugs,
6. the need for mechanical ventilation categorized as yes or no, in case - number of
respirator days,
7. length of stay in the Intensive Care Unit,
8. treatment outcome categorized as 28 day survival.